Exploring innovative strategies to enhance osteoporotic lumbar fusion: Efficacy of local delivery of prostaglandin EP4 receptor agonist KMN-159 and zoledronic acid in a rat model
Objectives and questions: Spinal fusion in patients with osteoporosis is challenging [ref:1]. rhBMP-2 is the only FDA-approved osteoinductive agent but has high costs and side effects [ref:2]. KMN-159, a novel prostaglandin EP4 receptor agonist, promotes spinal fusion in healthy [for full text, please go to the a.m. URL]
Institutions
- University Hospital Carl Gustav Carus (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2025-10-31
- DOI
- https://doi.org/10.3205/25dkou275
- Primary Topic
- Spine and Intervertebral Disc Pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00